




7860 Peters Road, F111 • Plantation, Florida 33324
(954) 723-0057 Phone • (954) 723-0353 Fax
email: info@naceonline.com

Challenges in Pulmonary and Critical Care: **2011**



December 3, 2011
Cleveland Clinic Florida
Jagelman Conference Center • 2950 Cleveland Clinic Blvd
Weston, Florida

Course Director
Franck Rahaghi, MD, MHS, FCCP

Program Evaluation
January 9, 2012

In December 2011, the National Association for Continuing Education (NACE) sponsored a CME activity, *Challenges in Pulmonary and Critical: 2011*, in Weston, FL.

This educational activity was designed to provide an update in the prevention, diagnosis, and management of pulmonary disease to pulmonologists, hospitalists, and other health care providers who treat patients with pulmonary diseases. Current findings in pulmonary research in such topics as lung cancer, COPD, anticoagulation, sleep medicine, pulmonary hypertension, and alpha-1 antitrypsin deficiency were presented.

In planning this CME activity, the NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

One hundred thirty eight healthcare practitioners registered to attend *Challenges in Pulmonary and Critical: 2011* in Weston, FL. One hundred two healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. Ninety four completed forms were received. The data collected is displayed in this report.

CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The National Association for Continuing Education designates this live activity for a maximum of 4 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Cleveland Clinic Florida and the National Association for Continuing Education. The Cleveland Clinic Florida is accredited by the ACCME to provide continuing medical education for physicians.

The Cleveland Clinic Florida designates this educational activity for a maximum of 2 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.


What is your professional degree?

Label	Frequency	Percent	Valid Percent
MD	58	61.70	62.37
DO	5	5.32	5.38
NP	10	10.64	10.75
PA	5	5.32	5.38
RN	10	10.64	10.75
Other	6	6.38	6.45
Total Valid	93	98.94	100.00
Total Missing	1	1.06	
Total	94	100.00	




What is your specialty?

Label	Frequency	Percent	Valid Percent
Primary Care	44	46.81	48.35
Endocrinology	1	1.06	1.10
Rheumatology	2	2.13	2.20
Pulmonology	20	21.28	21.98
Cardiology	1	1.06	1.10
Gastroenterology	1	1.06	1.10
OB/GYN	0	0.00	0.00
Other	22	23.40	24.18
Total Valid	91	96.81	100.00
Total Missing	3	3.19	
Total	94	100.00	




Upon completion of this activity, I can now - Discuss most recent data and recommendations regarding lung cancer screening; Describe current modalities for the diagnosis and staging of lung cancer; Discuss evidence based medicine treatment modalities for lung cancer:

Label	Frequency	Percent	Valid Percent
Yes	86	91.49	96.63
Somewhat	3	3.19	3.37
Not at all	0	0.00	0.00
Total Valid	89	94.68	100.00
Total Missing	5	5.32	
Total	94	100.00	




Upon completion of this activity, I can now - Explain the pathogenesis and diagnosis of COPD; Discuss findings of recent trials and evidence based treatment options for COPD; Explore new and evolving treatments including PDE-4 inhibitors for COPD:

Label	Frequency	Percent	Valid Percent
Yes	86	91.49	93.48
Somewhat	6	6.38	6.52
Not at all	0	0.00	0.00
Total Valid	92	97.87	100.00
Total Missing	2	2.13	
Total	94	100.00	




Upon completion of this activity, I can now - Explain criteria and treatment options for venous thrombosis prophylaxis; Discuss novel anti-coagulant therapies; Discuss treatment of pulmonary embolism in hospital:

Label	Frequency	Percent	Valid Percent
Yes	83	88.30	90.22
Somewhat	8	8.51	8.70
Not at all	1	1.06	1.09
Total Valid	92	97.87	100.00
Total Missing	2	2.13	
Total	94	100.00	




***Upon completion of this activity, I can now - Explain the pathophysiology of pulmonary arterial hypertension(PAH; Discuss the workup of patients suspected of having PAH; Discuss criteria for diagnosis and accurate assessments of disease severity in patients with PAH; List therapeutic options in the management of patients with PAH and discuss effective use of targeted treatment options for PAH:**

Label	Frequency	Percent	Valid Percent
Yes	73	77.66	91.25
Somewhat	7	7.45	8.75
Not at all	0	0.00	0.00
Total Valid	80	85.11	100.00
Total Missing	14	14.89	
Total	94	100.00	




***Upon completion of this activity, I can now - Explain the prevalence of alpha-1 antitrypsin deficiency(AATD); Discuss AATD testing by ancillary staff and the pulmonary function lab; Explore novel approaches to increase AATD testing:**

Label	Frequency	Percent	Valid Percent
Yes	63	67.02	90.00
Somewhat	6	6.38	8.57
Not at all	1	1.06	1.43
Total Valid	70	74.47	100.00
Total Missing	24	25.53	
Total	94	100.00	




Upon completion of this activity, I can now - Discuss the latest advances in diagnosis of sleep disorder and the indications and applications of home sleep testing; Describe the indications and applications of treatment of sleep apnea; Explain the indications and applications of certain drugs in sleep medicine:

Label	Frequency	Percent	Valid Percent
Yes	69	73.40	87.34
Somewhat	10	10.64	12.66
Not at all	0	0.00	0.00
Total Valid	79	84.04	100.00
Total Missing	15	15.96	
Total	94	100.00	




Overall, I would rate this activity as:

Label	Frequency	Percent	Valid Percent
Excellent	71	75.53	76.34
Very Good	20	21.28	21.51
Good	2	2.13	2.15
Fair	0	0.00	0.00
Poor	0	0.00	0.00
Total Valid	93	98.94	100.00
Total Missing	1	1.06	
Total	94	100.00	




Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

Label	Frequency	Percent	Valid Percent
Strongly Agree	59	62.77	63.44
Agree	30	31.91	32.26
Neutral	3	3.19	3.23
Disagree	1	1.06	1.08
Strongly Disagree	0	0.00	0.00
Total Valid	93	98.94	100.00
Total Missing	1	1.06	
Total	94	100.00	




Overall, this activity was effective in improving my knowledge in the content areas presented:

Label	Frequency	Percent	Valid Percent
Strongly Agree	67	71.28	72.04
Agree	26	27.66	27.96
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	93	98.94	100.00
Total Missing	1	1.06	
Total	94	100.00	




As a result of this activity, I have learned new strategies for patient care:

Label	Frequency	Percent	Valid Percent
Strongly Agree	60	63.83	65.22
Agree	29	30.85	31.52
Neutral	3	3.19	3.26
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	92	97.87	100.00
Total Missing	2	2.13	
Total	94	100.00	




How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid Percent
Very likely	58	61.70	63.04
Somewhat likely	26	27.66	28.26
Unlikely	1	1.06	1.09
Not applicable	7	7.45	7.61
Total Valid	92	97.87	100.00
Total Missing	2	2.13	
Total	94	100.00	




When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid Percent
Within 1 month	44	46.81	50.00
1-3 months	24	25.53	27.27
4-6 months	5	5.32	5.68
Not applicable	15	15.96	17.05
Total Valid	88	93.62	100.00
Total Missing	6	6.38	
Total	94	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Eduardo Oliveira, MD (Lung Ca):

Label	Frequency	Percent	Valid Percent
Excellent	76	80.85	84.44
Very Good	14	14.89	15.56
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	90	95.74	100.00
Total Missing	4	4.26	
Total	94	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Charlie Strange, MD (COPD):

Label	Frequency	Percent	Valid Percent
Excellent	79	84.04	84.95
Very Good	13	13.83	13.98
Good	1	1.06	1.08
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	93	98.94	100.00
Total Missing	1	1.06	
Total	94	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Victor Tapson, MD (Anticoag):

Label	Frequency	Percent	Valid Percent
Excellent	73	77.66	80.22
Very Good	12	12.77	13.19
Good	5	5.32	5.49
Fair	1	1.06	1.10
Unsatisfactory	0	0.00	0.00
Total Valid	91	96.81	100.00
Total Missing	3	3.19	
Total	94	100.00	




***In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD (PAH):**

Label	Frequency	Percent	Valid Percent
Excellent	65	69.15	84.42
Very Good	11	11.70	14.29
Good	1	1.06	1.30
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	77	81.91	100.00
Total Missing	17	18.09	
Total	94	100.00	




***In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD (AAT):**

Label	Frequency	Percent	Valid Percent
Excellent	60	63.83	88.24
Very Good	8	8.51	11.76
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	68	72.34	100.00
Total Missing	26	27.66	
Total	94	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Laurence Smolley, MD (Sleep):

Label	Frequency	Percent	Valid Percent
Excellent	56	59.57	74.67
Very Good	15	15.96	20.00
Good	4	4.26	5.33
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	75	79.79	100.00
Total Missing	19	20.21	
Total	94	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Eduardo Oliveira, MD (Lung Ca):

Label	Frequency	Percent	Valid Percent
Excellent	83	88.30	91.21
Very Good	8	8.51	8.79
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	91	96.81	100.00
Total Missing	3	3.19	
Total	94	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Charlie Strange, MD (COPD):

Label	Frequency	Percent	Valid Percent
Excellent	83	88.30	89.25
Very Good	9	9.57	9.68
Good	1	1.06	1.08
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	93	98.94	100.00
Total Missing	1	1.06	
Total	94	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Victor Tapson, MD (Anticoag):

Label	Frequency	Percent	Valid Percent
Excellent	79	84.04	85.87
Very Good	11	11.70	11.96
Good	2	2.13	2.17
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	92	97.87	100.00
Total Missing	2	2.13	
Total	94	100.00	




***To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD (PAH):**

Label	Frequency	Percent	Valid Percent
Excellent	72	76.60	88.89
Very Good	7	7.45	8.64
Good	2	2.13	2.47
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	81	86.17	100.00
Total Missing	13	13.83	
Total	94	100.00	




***To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD (AAT):**

Label	Frequency	Percent	Valid Percent
Excellent	67	71.28	90.54
Very Good	7	7.45	9.46
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	74	78.72	100.00
Total Missing	20	21.28	
Total	94	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Laurence Smolley, MD (Sleep):

Label	Frequency	Percent	Valid Percent
Excellent	68	72.34	83.95
Very Good	11	11.70	13.58
Good	2	2.13	2.47
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	81	86.17	100.00
Total Missing	13	13.83	
Total	94	100.00	




Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent	Valid Percent
Topics covered	74	78.72	79.57
Location/ease of access	60	63.83	64.52
Faculty	45	47.87	48.39
Earn CME credits	62	65.96	66.67
Total Valid	93	98.94	100.00
Total Missing	1	1.06	
Total	94	100.00	



Future CME activities concerning this subject matter are necessary:

Label	Frequency	Percent	Valid Percent
Strongly agree	51	54.26	59.30
Agree	30	31.91	34.88
Neutral	5	5.32	5.81
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	86	91.49	100.00
Total Missing	8	8.51	
Total	94	100.00	



What is your professional degree?

Comment
RRT
RRT
LPN
LPN
CPC
PharmD

What is your specialty?

Comment
Occupational Health
Surgery
Psychiatry
Mental Health
Critical Care
Critical Care
Clinical Lab
Clinical Lab
Hospitalist
Geriatrics
Dermatology

As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment
Medical management of PVT/PF and pulmonary HTN
Update management of diseases, improve patient care and safety
Will try to refer more patients for improved care (I work in the jail system and some treatment is limited) i.e., snorers referred for sleep apnea studies
PE management/diagnosis, anticoagulation therapeutics
Do least diagnostic procedures that yields the most result. Follow FDA treatment but don't shy away from promising non-FDA approved drugs
Earlier Dx & Rx of pulmonary embolism, Dx of PAH + Rx
Medication use/Diagnostic approach
Be on the lookout for PE, Listen to patient complaints carefully (when applicable), Early detection of COPD, do not overlook symptoms
EGFR status guided therapy, New indications for Pradaxa
Spirometry for COPD patients, thinking about low dose CT for lung ca screening
New therapies regarding treating pulmonary embolism, COPD, Pulmonary cancer, Pulmonary hypertension
(1) Discuss new anticoagulants, (2) Discourage home sleep studies
Better knowledge of signs/symptoms to identify/test A1A patients

Comment
Increase preventative diagnostic measures. Improve communication with patients and family. Review all management protocols
Reconsider Daliresp
Use of more spirometry, More knowledgeable with treatment of lung cancer, More aware of new and coming treatments
Doing more spirometry tests on at risk patients, Innovative tests such as EBUS, EBN
Use of NEPAP, use of new oral anticoagulants, lung cancer screening
Possibly adding Daliresp in exacerbator of COPD, Nasal EPAP
New approaches shown in the lectures to manage these patients
COPD management, Diagnosing procedures for lung cancer
Screen more for COPD
Screen patients for COPD with spirometry
Disease management for COPD, Risk stratification of submassive PE
Enhanced genetic screening options, obtaining more targeted history
Treatment options for COPD
New review on anticoagulation therapy, institution of home sleep monitor program, new views on lung cancer treatment, look at new treatment options for PAH i.e. combination therapy/Alpha -/education with patients
Tumor markers in lung cancer
New therapies, both pharmacological and management strategies
(1) Treatment strategies, (2) Testing options
Management of PH and new focus in the treatment of sleep apnea and lung cancer
How to treat patient with PE, New guidelines, COPDs and the use of spirometries
Present new information to staff immediately
Improve diagnosis techniques and therapy
Ask questions, listen, refer to physicians - hopefully to those who could help
Lung cancer workup, COPD exacerbation
Implementation of strategy of diagnosis and management
The strategies are up to date with common sense and the speakers with category
Implement spirometry at the office, Test all COPD patients for AAT
Spirometry test for each patient, COPD - more extensive treatment early with frequent follow-up
Diagnostic option for lung cancer, lung cancer clarification and type of treatment
(1) Use of low dose CAT scan in lung cancer (2) use of spirometry in COPD (3) Suspect pulm embolism in all resp disease (4) Need for heart cath in PAH Dx, use multiple drugs, be aggressive (5) screen for AATD, (6) Use home sleep study if pt refuses lab study
Follow recommended strategies like recommending ECHO for Pulm. HTN, do tests that yield best overall results
To be more aggressive in diagnosis and treatment of COPD, Diagnosis of lung CA (screening), Refer patients with sleep problems to specialist before treatment
A1A testing, use of newer anticoagulants, changes in COPD testing
Consider new pulm reduction techniques, seek to expand team of specialists on lung cancer
In depth evaluation of patient with pulmonary embolism, Increase use of spirometry to diagnose COPD, Increased use of sleep study where patients present supportive signs and symptoms

What topics would you like to see offered as CME activities in the future?

Comment
Musculoskeletal medicine/pain management
Pulmonary HTN
Oncology, Infectious diseases
Any
Any topic
Very similar topics/subjects
Genetics in medicine, Newer drug therapies for treatment of pulmonary diseases, Cardiac disease
ILD
Cardiovascular, Metabolic Syndrome, Diabetes
Same one as today. Very good
Infectious diseases
It's all good
Asthma, Pulmonary fibrosis ongoing trials
Hepatic disorders
General medicine
Bronchiatitis
Radiation/oncology, Hematology
ACS, CHF
Psychiatry topics including pharmacology
Oncology topics
Critical care - recent developments
Screening/diagnosis of breast cancer, new treatment options
Cystic fibrosis, Bronchiectasis, Asthma, Pulmonary infectious diseases
Autoimmune disorders
Bipolar disorder, dementias, schizophrenia, other mood disorders
Interventional pulmonary procedure update
Asthma, Cystic fibrosis
Because I'm not a physician, just a RT, I would like a topic on managing patients on ventilators
I particularly am interested in emergency/urgent care topics
Cardiology, women's health, hematology
Any in medicine
Viral hepatitis, autoimmune hepatitis
CV, Lung, Neuro
Gastro-intestinal diseases
Diabetes, hypertension, ASHD, Metabolic Syndrome
Obesity and overweight and what else?! Hepatitis C update
Topics of general interest
More critical care
Healthcare reform laws, Neuro/Endocrine topics
Neurology, IBS - ulcerative colitis, etc
Complicated diagnosis and primary care physician
Diabetes, prevention of coronary disease

Comment
Same as current presentation
COPD, CAD, DM, Symptom control
Endocrinology
PAH, ILD

Additional comments:

Comment
OK
I like the location and the meeting room and the size of the meetings
An excellent symposium as usual
Good topics
Good coverage of each topic
Very nice NACE representative
None
Interesting lectures
Great conference, thanks
Excellent conference
Excellent program
Good conference
Thank you
Overall talks were very informative
Organized presentation, good speakers
Thank you, Dr. Rahaghi for a wonderful and educational seminar. You are a gifted speaker
Always informative, my second year attending, look forward to next year
Thoroughly enjoyed it
I'm a respiratory therapist who was encouraged to attend this conference by my employer Dr. Fred Grunberg. As his office manager, I feel these topics helped to understand our patients and their conditions more now that I did before
Thank you
Excellent overall
Speakers are all very knowledgeable.
Thank you
Thank you
Excellent
Thank you
Thank you
Conference was excellent and well presented
NACE always excellent speakers
Excellent
Excellent conference
Dr. Tapson - the lecture was excellent
Excellent meeting
Very good conference. I attend every year and look forward to next year's conference
Well done
I especially enjoyed Dr. Rahaghi's presentations